earnings
confidence high
sentiment positive
materiality 0.80
BeOne Medicines Q2 revenue up 30% to $1.7B; raises FY2026 guidance
BeOne Medicines Ltd.
2026-Q2 EPS reported
$0.31
revenue$3,218,509,000
- Q2 total revenue $1.71B (+30% YoY); BRUKINSA revenue $1.2B (+31% YoY).
- GAAP diluted EPS $2.05; non-GAAP diluted EPS $3.84 (up 71% YoY).
- Raised FY2026 revenue guidance to $6.6-6.8B; GAAP op income $1.0-1.1B.
- Q2 free cash flow $435M (+98% YoY); six-month total revenue $3.22B (+32% YoY).
- CEO cites strong hematology franchise and pipeline momentum.